RNTX Rein Therapeutics, Inc.

NASDAQ
$0.34

Rein Therapeutics, Inc. (RNTX) is expected to report earnings on February 15, 2027, before the market open. The consensus earnings estimate is a loss of $0.12 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -32.6% since its last earnings release on November 16, 2026.

Rein Therapeutics Beat Consensus Estimates
Monday, November 16, 2026 · 7:30 AM ET
Earnings Date
4th Quarter, Dec 2026
Feb 15
Monday · 6:45 AM ET
Earnings Whisper
-
vs ($0.12)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $0.38

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Rein Therapeutics, Inc.

Rein Therapeutics is a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications. Rein Therapeutics, formerly known as Aileron Therapeutics Inc., is based in AUSTIN, Texas.

Sector

Healthcare

Industry

Biotechnology

Charts powered in part by Lightweight Charts™ by TradingView.